Rifampicin
- Generic Name
- Rifampicin
- Brand Names
- Isonarif, Rifadin, Rifamate, Rifater, Rofact
- Drug Type
- Small Molecule
- Chemical Formula
- C43H58N4O12
- CAS Number
- 13292-46-1
- Unique Ingredient Identifier
- VJT6J7R4TR
- Background
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericid...
- Indication
Rifampin is indicated for the treatment of tuberculosis and tuberculosis-related mycobacterial infections. In combination with pyrazinamide and isoniazid, it is used in the initial phase of the short-course treatment of pulmonary tuberculosis.
- Associated Conditions
- Cholestatic pruritus, MRSA Infections, Prosthetic Joint Infections, Asymptomatic Neisseria meningitidis carrier of the nasopharynx, Initial phase Tuberculosis, Late phase Tuberculosis
- Associated Therapies
- Antibacterial therapy
Drug-drug Interaction Between Belumosudil, Itraconazole, Rifampicin, Rabeprazole, and Omeprazole in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2018-05-21
- Last Posted Date
- 2022-05-25
- Lead Sponsor
- Kadmon Corporation, LLC
- Target Recruit Count
- 73
- Registration Number
- NCT03530995
- Locations
- 🇬🇧
Quotient Sciences Ltd, Ruddington, Nottingham, United Kingdom
A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2018-04-03
- Last Posted Date
- 2022-04-18
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT03486314
- Locations
- 🇺🇸
Greenville Health System - Institute for Translational Oncology Research, Greenville, South Carolina, United States
🇺🇸Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Emory University, Atlanta, Georgia, United States
Rifampicin vs Rifabutin in HIV/AIDS Patients Combined With Tuberculosis
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2018-04-24
- Lead Sponsor
- Shanghai Public Health Clinical Center
- Target Recruit Count
- 230
- Registration Number
- NCT03478033
- Locations
- 🇨🇳
Shanghai Public Health Clinical Center, Shanghai, Shanghai, China
Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis
- First Posted Date
- 2018-03-22
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- University College, London
- Target Recruit Count
- 675
- Registration Number
- NCT03474198
- Locations
- 🇮🇩
Saiful Anwar Hospital, Malang, Indonesia
🇺🇬Joint Clinical Research Centre, Mbarara, Uganda
🇺🇬Infectious Diseases Institute, Kampala, Uganda
Drug-drug Interaction Between Rifampicin and Progestins/Ethinylestradiol and Midazolam
- First Posted Date
- 2017-11-27
- Last Posted Date
- 2020-04-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 68
- Registration Number
- NCT03353857
- Locations
- 🇩🇪
CRS Clinical-Research-Services Mannheim GmbH, Mannheim, Baden-Württemberg, Germany
🇩🇪CRS Clinical-Research-Services Mönchengladbach GmbH, Mönchengladbach, Nordrhein-Westfalen, Germany
A Study to Evaluate the Effect of 2 Drugs on the Pharmacokinetics of BMS-986205 in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2018-02-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 53
- Registration Number
- NCT03346837
- Locations
- 🇺🇸
PPD, Austin, Texas, United States
Study Evaluating the Effects of Food, Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of CC-122
- Conditions
- Interventions
- First Posted Date
- 2017-11-13
- Last Posted Date
- 2019-01-16
- Lead Sponsor
- Celgene
- Target Recruit Count
- 81
- Registration Number
- NCT03340662
- Locations
- 🇺🇸
PPD Phase 1 Clinic, Austin, Texas, United States
Comparison Between Rifampicin and Gemifloxacin and Ciprofloxacin in Treatment of Rhinoscleroma
- Conditions
- Interventions
- First Posted Date
- 2017-10-30
- Last Posted Date
- 2018-02-13
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 60
- Registration Number
- NCT03326050
- Locations
- 🇪🇬
Asmaa Ahmed, Assiut, Egypt
Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386)
- First Posted Date
- 2017-10-17
- Last Posted Date
- 2020-01-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 32
- Registration Number
- NCT03311841
- Locations
- 🇺🇸
Clinical Pharmacology of Miami ( Site 0001), Hialeah, Florida, United States
🇺🇸Orlando Clinical Research Center ( Site 0002), Orlando, Florida, United States
This Study Tests the Effect of Certain Medicines on the Transport of Other Medicines in the Body of Healthy Men
- Conditions
- Interventions
- First Posted Date
- 2017-10-11
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 45
- Registration Number
- NCT03307252
- Locations
- 🇩🇪
CTC North GmbH & Co. KG, Hamburg, Hamburg, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.